Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Weihao Chen, Yuting Yan, Ying Yu, Yuxi Li, Xiong Wenjie, Xinyi Zhang, Tingyu Wang, Wei LIU, Weiwei Sui, Zhen Yu, Mu Hao, Gang An, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3593.

https://doi.org/10.1182/blood-2025-3593

Published: 2025

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

Liang Wang, Yuting Yan, Lugui Qiu, Tingyu Wang, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2025-2126

Published: 2025

Journal Articles

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu, Xiong Wenjie, Rui Lv, Tengteng Yu, Wei LIU, Yan Xu, Weiwei Sui, Wenyang Huang, Shuaishuai Zhang, Qi Wang, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2025-2124

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

Ying Yu, Yuxi Li, Rui Cui, Tingyu Wang, Yin WU, Chenglu Yuan, Yuqing Chen, Huanling Zhu, Yuting Yan, Wenjie Xiong, Shuhui Deng, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2025-3648

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Wen Zhang, Wei LIU, Ting Xie, Tingyu Wang, Xiong Wenjie, Hesong Zou, Yi Wang, Shuhua Yi, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2025-7165

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Xiong Wenjie, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Wei Liu, Huimin Liu, Gang An, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2024-198864

Published: 2024

Journal Articles

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Yuting Yan, Yulan Zhou, Weihao Chen, Jun Wang, Tingyu Wang, Ying Yu, Yujiao Jia, Zhen Yu, Lugui Qiu, Fei Li, Shuhua Yi

Blood (2024) 144 (Supplement 1): 4624.

https://doi.org/10.1182/blood-2024-207323

Published: 2024

Journal Articles

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Shuhua Yi, Tingyu Wang, Fei Li, Jingdong Zhang, Xingli Zou, Yanping Ma, Lugui Qiu

Blood (2024) 144 (Supplement 1): 1875.1.

https://doi.org/10.1182/blood-2024-201175

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Different Large Granular Lymphocyte Count Drew Distinguish Characteristics in Large Granular Lymphocytic Leukemia

Ying Yu, Yuxi Li, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Xiong Wenjie, Yuting Yan, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2024-202299

Published: 2024

Journal Articles

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Xiong Wenjie, Yuting Yan, Ying Yu, Tingyu Wang, Wei Liu, Gang An, Weiwei Sui, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2024-198882

Published: 2024

Journal Articles

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Jingjing Yuan, Li Yuxi, Yuting Yan, Xiong Wenjie, Tengteng Yu, Tingyu Wang, Ying Yu, Lugui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2024-206886

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Different Large Granular Lymphocyte Count Drew Distinguish Characteristics in Large Granular Lymphocytic Leukemia

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Lenalidomide and Obinutuzumab in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only